The Food and Drug Administration proposed new rules that will provide pharmaceutical companies more latitude in promoting off-label uses of medicines, biologics and medical devices.
The Food and Drug Administration proposed new rules that will provide pharmaceutical companies more latitude in promoting off-label uses of medicines, biologics and medical devices.
If the rules are finalized and implemented as a provision of the FDA Modernization Act of 1997, sales reps will be empowered to share information such as peer-reviewed journal articles about off-label uses with health care practitioners, pharmacy benefit managers, health insurance issuers, group health plans and state and federal agencies.
In the past, pharmaceutical companies had to wait until the FDA approved a supplemental application before they could disseminate even reliable information about unapproved uses.
The new rules specify that off-label, unapproved information can only be disseminated under certain conditions: Companies must study the unapproved uses and have submitted, or made plans to submit, applications for formal FDA approval, and the information must be reliable and balanced. It may be an unabridged reprint or copy of a peer-reviewed scientific or medical journal article, or an unabridged reference publication about a clinical investigation that is considered scientifically sound.
The unapproved uses must not pose a significant risk to the public health, be false or misleading or have been derived without permission from clinical research conducted by another pharmaceutical manufacturer. Companies must also include certain disclosures with the information, including official labeling, a bibliography of other articles pertaining to the new use and a statement indicating that the new use has not been approved by the FDA.
To keep pharmaceutical companies motivated to acquire official FDA approval, companies will also have to submit a copy of the information to the FDA within 60 days prior to disseminating the information. PR
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.